The treatment of hormone-refractory prostate cancer: docetaxel and beyond
- PMID: 17021642
- PMCID: PMC1578715
Item in Clipboard
The treatment of hormone-refractory prostate cancer: docetaxel and beyond
Rev Urol.
2006.
Abstract
Two randomized clinical trials demonstrated a survival benefit of 20% to 24% with docetaxel-based therapy when compared with survival with mitoxantrone and prednisone after failure of androgen ablation therapy. These studies supported the approval of docetaxel-based therapy for the treatment of metastatic hormone-refractory prostate cancer by the US Food and Drug Administration in May 2005. Clinical trials in hormone-refractory prostate cancer are now focused on building on the survival improvement seen with docetaxel-based therapy. This article presents a summary of some of the more promising treatments and regimens for advanced prostate cancer.
Similar articles
-
Approval summary: Docetaxel in combination with prednisone for the treatment of androgen-independent hormone-refractory prostate cancer.Clin Cancer Res. 2004 Dec 15;10(24):8147-51. doi: 10.1158/1078-0432.CCR-04-1402. Clin Cancer Res. 2004. PMID: 15623588 Clinical Trial.
-
Recent docetaxel studies establish a new standard of care in hormone refractory prostate cancer.Can J Urol. 2005 Feb;12 Suppl 1:81-5. Can J Urol. 2005. PMID: 15780173 Review.
-
New paradigms for advanced prostate cancer.Rev Urol. 2007;9 Suppl 2(Suppl 2):S3-S12. Rev Urol. 2007. PMID: 17554403 Free PMC article.
-
Future directions in the treatment of androgen-independent prostate cancer.Urology. 2005 Jun;65(6 Suppl):8-12. doi: 10.1016/j.urology.2005.04.020. Urology. 2005. PMID: 15939077 Review.
-
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.N Engl J Med. 2004 Oct 7;351(15):1513-20. doi: 10.1056/NEJMoa041318. N Engl J Med. 2004. PMID: 15470214 Clinical Trial.
Cited by
-
Distinct mechanisms mediating therapy-induced cellular senescence in prostate cancer.Cell Biosci. 2022 Dec 15;12(1):200. doi: 10.1186/s13578-022-00941-0. Cell Biosci. 2022. PMID: 36522745 Free PMC article. Review.
-
Dual action of NSC606985 on cell growth and apoptosis mediated through PKCδ in prostatic cancer cells.Int J Oncol. 2017 Nov;51(5):1601-1610. doi: 10.3892/ijo.2017.4138. Epub 2017 Sep 27. Int J Oncol. 2017. PMID: 29048618 Free PMC article.
-
Novel docetaxel-loaded nanoparticles based on poly(lactide-co-caprolactone) and poly(lactide-co-glycolide-co-caprolactone) for prostate cancer treatment: formulation, characterization, and cytotoxicity studies.Nanoscale Res Lett. 2011 Mar 28;6(1):260. doi: 10.1186/1556-276X-6-260. Nanoscale Res Lett. 2011. PMID: 21711774 Free PMC article.
-
Targeting Solid Lipid Nanoparticles with Anisamide for Docetaxel Delivery to Prostate Cancer: Preparation, Optimization, and In-vitro Evaluation.Iran J Pharm Res. 2021 Winter;20(1):327-338. doi: 10.22037/ijpr.2020.113436.14302. Iran J Pharm Res. 2021. PMID: 34400962 Free PMC article.
-
Retinoblastoma tumor suppressor status is a critical determinant of therapeutic response in prostate cancer cells.Cancer Res. 2007 Jul 1;67(13):6192-203. doi: 10.1158/0008-5472.CAN-06-4424. Cancer Res. 2007. PMID: 17616676 Free PMC article.
References
-
- Petrylak DP. Chemotherapy for androgen-independent prostate cancer. Semin Urol Oncol. 2002;20:31–35. - PubMed
-
- Nelson J, Bagnato A, Battistini B, et al. The endothelin axis: emerging role in cancer. Nat Rev Cancer. 2003;3:110–116. - PubMed
-
- Carducci MA, Padley RJ, Breul J, et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol. 2003;21:679–689. - PubMed
-
- Vogelzang N, Nelson J, Schulman C, et al. Meta-analysis of clinical trials of atrasentan 10 mg in metastatic hormone-refractory prostate cancer. Proc Am Soc Clin Oncol. 2005;23:393S.
-
- Hussain M, Tangen CM, Lara PN, Jr, et al. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. J Clin Oncol. 2005;23:8724–8729. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources